BIOVIC B Stock Overview
A biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Biovica International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.74 |
| 52 Week High | SEK 3.40 |
| 52 Week Low | SEK 1.40 |
| Beta | 1.42 |
| 1 Month Change | -6.96% |
| 3 Month Change | -34.29% |
| 1 Year Change | -36.80% |
| 3 Year Change | -95.26% |
| 5 Year Change | -85.15% |
| Change since IPO | -85.46% |
Recent News & Updates
Recent updates
Is Biovica International (STO:BIOVIC B) In A Good Position To Invest In Growth?
Dec 03
Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?
Jul 18Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 02Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation
Aug 02Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Feb 17A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)
Jan 19Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth
Nov 11We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth
Aug 06We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn
Mar 20Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?
Feb 22What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?
Jan 26The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders
Dec 31
Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 05Shareholder Returns
| BIOVIC B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -19.4% | 1.2% | -2.7% |
| 1Y | -36.8% | 13.8% | 4.6% |
Return vs Industry: BIOVIC B underperformed the Swedish Biotechs industry which returned 13.8% over the past year.
Return vs Market: BIOVIC B underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| BIOVIC B volatility | |
|---|---|
| BIOVIC B Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: BIOVIC B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BIOVIC B's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 27 | Anders Rylander | www.biovica.com |
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation.
Biovica International AB (publ) Fundamentals Summary
| BIOVIC B fundamental statistics | |
|---|---|
| Market cap | SEK 157.02m |
| Earnings (TTM) | -SEK 115.45m |
| Revenue (TTM) | SEK 7.24m |
21.7x
P/S Ratio-1.4x
P/E RatioIs BIOVIC B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIC B income statement (TTM) | |
|---|---|
| Revenue | SEK 7.24m |
| Cost of Revenue | SEK 1.02m |
| Gross Profit | SEK 6.22m |
| Other Expenses | SEK 121.67m |
| Earnings | -SEK 115.45m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
Mar 13, 2025
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 85.86% |
| Net Profit Margin | -1,593.93% |
| Debt/Equity Ratio | 0% |
How did BIOVIC B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biovica International AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Dan Akschuti | Pareto Securities |
| Johan Unnerus | Redeye |